利用者:Hanabishi/作業場00
Lance-Adams syndrome (LAS) is a sequela of hypoxic encephalopathy due to respiratory arrest, airway obstruction, cardiac arrest, etc. , several days after the onset of hypoxic encephalopathy. A condition that presents with functional myoclonus associated with increased cortical excitability in a few weeks.[1][2][3][4] It was first reported by James Lance and Raymond Adams in 1963.[5][6]
It is a disease that presents Myoclonus during operation as a sequela of hypoxic disorders in the brain due to asphyxiation and cardiopulmonary arrest.[2][3] It is exacerbated by mental and physical anxiety such as intention, intentional movement, and tension.[2][3]
Pathology
[編集]It appears due to Basal ganglia lesions due to hypoxic encephalopathy .[2]
Treatment
[編集]Clonazepam and Valproate , which enhance serotonin and GABAA receptor, are widely used as therapeutic agents . [2][4][7] It has been reported that Levetiracetam was effective in cases in which clonazepam and valproic acid were ineffective.[8][9][10] Other reports have shown that piracetam has been shown to be effective.[4][11]
Perampanel
[編集]From around 2017, reports that Perampanel are effective have been gathered, and cases of complete cure have been reported.[12][13][14][15][16]
In April 2021, a group at Kyoto University reported a case of Lance Adams syndrome 11 years after onset due to hypoxic encephalopathy caused by a bronchial asthma attack, and in March 2022, a group at Kitasato University reported a case of Lance Adams syndrome after a hanging neck injury 1 year and 6 months after onset. There are an increasing number of reports showing improvement even in chronic cases, such as a case report of a patient who was able to hold a standing position after treatment with perampanel and significant improvement in motor myoclonus.[16][17]
References
[編集]- ^ Y. X. Zhang, J. R. Liu u. a.: Lance-Adams syndrome: a report of two cases. In: Journal of Zhejiang University. Science. B. Band 8, Nummer 10, Oktober 2007, S. 715–720, ISSN 1673-1581. doi:10.1631/jzus.2007.B0715. PMID 17910113. PMC 1997224. (Review).
- ^ a b c d e ベッドサイドの神経の診かた 改訂17版 P179 南山堂 ISBN 978-4525247171
- ^ a b c 神経診察クローズアップ-正しい病巣診断のコツ 改訂2版 P104 メジカルビュー社 ISBN 978-4758303804
- ^ a b c 星野愛, 熊田聡子, 横地房子, 八谷靖夫, 花房由季子, 冨田直, 沖山亮一, 栗原栄二, 「十分量のpiracetam投与が有効であったLance-Adams症候群の1例」『脳と発達』 2009年 41巻 5号 p.357-360, , doi:10.11251/ojjscn.41.357
- ^ Lance, J.W. and R.D. Adams: !2THE SYNDROME OF INTENTION OR ACTION MYOCLONUS AS A SEQUEL TO HYPOXIC ENCEPHALOPATHY." Brain 86, p.111-136 (1963), doi:10.1093/brain/86.1.111
- ^ 長山隆, 山根清美, 阿部裕光, 島國義, 高橋正宏, 太田舜二, 小林逸郎, 竹宮敏子, 丸山勝一「Postanoxic Encephalopathy の1症例 : 特に Lance-Adams症候群について」『東京女子医科大学雑誌』第54巻第10号、東京女子医科大学学会、1984年10月、1112-1117頁、ISSN 0040-9022、NAID 120002357826。
- ^ S. Frucht, S. Fahn: The clinical spectrum of posthypoxic myoclonus. In: Movement disorders : official journal of the Movement Disorder Society. Band 15, Suppl 1, 2000, S. 2–7, ISSN 0885-3185. PMID 10755265. (Review).
- ^ KraussGL,Bergin A,Kramer RE,Cho YW,ReichiSG."Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam." Newrology 2001:56:411-2, doi:10.1212/WNL.57.6.1144-b.
- ^ P. Genton, P. Gélisse (2000), “Antimyoclonic effect of levetiracetam.” (German), Epileptic Disord 2: pp. 209–212
- ^ G. L. Krauss, A. Bergin, R. E. Kramer u. a. (2001), “Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam.” (German), Neurology 56: pp. 411–412
- ^ 林元久,木下喬弘,山川一馬,松田宏樹,藤見聡『日本救急医学会雑誌』第28巻第9号、日本救急医学会、東京都文京区、2017年9月、623頁。
- ^ Goldsmith D, Minassian BA. "Efficacy and tolerability of perampanel in ten patients with Lafora disease." Epilepsy Behav 2016;62:132-135
- ^ Crespel A, Gelisse P, Tang NP, et al. Perampanel in 12 patient swith Unverricht-Lundborg disease. Epilepsia 2017;58:543-547, doi:10.1016/j.yebeh.2016.06.041.
- ^ Steinhoff BJ, Bacher M, Kurth C, et al. "Add-on perampanel in Lance-Adams syndrome." Epilepsy Behav Case Rep 2016;6:28-29, doi:10.1016/j.ebcr.2016.05.001.
- ^ Shiraishi H, Egawa K, Ito T, et al. "Efficacy of perampanel for controlling seizures and improving neurological dysfunction in a patient with dentatorubral-pallidoluysian atrophy (DRPLA)." Epilpsy Behav Case Rep 2017;8:44-46, doi:10.1016/j.ebcr.2017.05.004.
- ^ a b Daiji Saita, Satoru Oishi, Masanori Saito "Administration of a small dose of perampanel improves walking ability in a case of Lance-Adams Syndrome" psychiatry and clinical neurosciences 2022;Volume76, Issue3:89-89
- ^ 齋藤和幸、大井和起、稲葉彰、小林正樹、池田昭夫、 和田義明「長期経過で持続した Lance-Adams 症候群の重症ミオクローヌスにペランパネルが奏効した 1 例」『臨床神経学』第61巻、日本神経学会、東京都文京区、2021年4月、18-23頁、ISSN 0009-918X、ONLINE ISSN 1882-0654、2021年7月4日閲覧。